Solventum (NYSE:SOLV) Given New $71.00 Price Target at The Goldman Sachs Group

Solventum (NYSE:SOLV) had its price target upped by The Goldman Sachs Group from $63.00 to $71.00 in a report published on Monday,Benzinga reports. The firm currently has a sell rating on the stock.

SOLV has been the subject of several other research reports. Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday. Morgan Stanley increased their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Mizuho assumed coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target for the company. Finally, Wells Fargo & Company upped their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, Solventum currently has a consensus rating of “Hold” and an average price target of $78.86.

Solventum Price Performance

Shares of NYSE:SOLV opened at $80.07 on Monday. The business has a 50 day moving average price of $72.78 and a 200 day moving average price of $70.20. Solventum has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a market cap of $13.83 billion and a price-to-earnings ratio of 29.12. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Hedge Funds Weigh In On Solventum

Several hedge funds and other institutional investors have recently modified their holdings of the stock. New York Life Investment Management LLC lifted its position in shares of Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after buying an additional 136 shares during the period. Blue Trust Inc. lifted its position in shares of Solventum by 2.1% during the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock worth $549,000 after buying an additional 161 shares during the period. MML Investors Services LLC raised its position in Solventum by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after purchasing an additional 168 shares during the last quarter. EP Wealth Advisors LLC raised its position in Solventum by 3.6% in the 4th quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company’s stock valued at $348,000 after purchasing an additional 181 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in Solventum by 2.2% in the 4th quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock valued at $584,000 after purchasing an additional 192 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.